Healthcare provider profile · identity verified

Sashibindu Amara, MD

Internal Medicine · BURLINGAME, CA · NPI 1194832493

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	583	149
Amlodipine Besylate	Amlodipine Besylate	304	78
Levothyroxine Sodium	Levothyroxine Sodium	230	62
Gabapentin	Gabapentin	167	43
Losartan Potassium	Losartan Potassium	163	47
Lisinopril	Lisinopril	143	40
Omeprazole	Omeprazole	95	29
Trazodone Hcl	Trazodone Hcl	88	24
Pantoprazole Sodium	Pantoprazole Sodium	86	25
Alendronate Sodium	Alendronate Sodium	76	23
Metoprolol Succinate	Metoprolol Succinate	75	24
Rosuvastatin Calcium	Rosuvastatin Calcium	75	22
Zolpidem Tartrate	Zolpidem Tartrate	70	16
Lorazepam	Lorazepam	63	27
Eliquis	Apixaban	60	13
Sertraline Hcl	Sertraline Hcl	56	12
Metformin Hcl	Metformin Hcl	53	18
Escitalopram Oxalate	Escitalopram Oxalate	52	12
Hydrochlorothiazide	Hydrochlorothiazide	52	18
Valsartan	Valsartan	52	15
Fluticasone Propionate	Fluticasone Propionate	48	20
Albuterol Sulfate Hfa	Albuterol Sulfate	47	24
Montelukast Sodium	Montelukast Sodium	46	13
Allopurinol	Allopurinol	43	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	42	13
Ozempic	Semaglutide	40	suppressed
Simvastatin	Simvastatin	40	12
Duloxetine Hcl	Duloxetine Hcl	38	suppressed
Carvedilol	Carvedilol	36	suppressed
Clonazepam	Clonazepam	36	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	34	suppressed
Cephalexin	Cephalexin	33	23
Meloxicam	Meloxicam	33	17
Pravastatin Sodium	Pravastatin Sodium	31	suppressed
Famotidine	Famotidine	30	15
Atenolol	Atenolol	29	suppressed
Clopidogrel	Clopidogrel Bisulfate	29	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	29	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	28	12
Celecoxib	Celecoxib	27	suppressed
Furosemide	Furosemide	27	suppressed
Lovastatin	Lovastatin	27	suppressed
Donepezil Hcl	Donepezil Hcl	23	suppressed
Tizanidine Hcl	Tizanidine Hcl	23	suppressed
Valacyclovir	Valacyclovir Hcl	23	suppressed
Ipratropium Bromide	Ipratropium Bromide	22	14
Pregabalin	Pregabalin	22	suppressed
Synthroid	Levothyroxine Sodium	22	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	21	suppressed
Januvia	Sitagliptin Phosphate	21	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	21	suppressed
Azithromycin	Azithromycin	20	19
Sumatriptan Succinate	Sumatriptan Succinate	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	suppressed
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Terazosin Hcl	Terazosin Hcl	19	suppressed
Finasteride	Finasteride	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Symbicort	Budesonide/Formoterol Fumarate	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	12
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	17	16
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Potassium Chloride	Potassium Chloride	16	suppressed
Alprazolam	Alprazolam	15	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Torsemide	Torsemide	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Trospium Chloride	Trospium Chloride	15	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	14	suppressed
Levetiracetam	Levetiracetam	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	13	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Lacosamide	Lacosamide	12	suppressed
Citalopram Hbr	Citalopram Hydrobromide	11	suppressed
Jardiance	Empagliflozin	11	suppressed
Metformin Hcl Er	Metformin Hcl	11	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error